TOP > 外国特許検索 > NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME

NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME NEW

外国特許コード F190009998
整理番号 (S2018-0527-N0)
掲載日 2019年10月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP013132
国際公開番号 WO 2019189331
国際出願日 平成31年3月27日(2019.3.27)
国際公開日 令和元年10月3日(2019.10.3)
優先権データ
  • 特願2018-061397 (2018.3.28) JP
発明の名称 (英語) NOVEL K95-5901-1 SUBSTANCE AND METHOD FOR PRODUCING SAME NEW
発明の概要(英語) As a result of searching for an antibiotic substance effective for multidrug-resistant Mycobacterium tuberculosis in a microorganism culture solution, the present inventors discovered a novel substance K95-5901-1 having the following structure, within products of an actinobacterium, Actinoplanes sp. K95-5901. This substance expresses a proliferation-inhibiting activity to multidrug-resistant Mycobacterium tuberculosis at a concentration lower than micromole level, and has a very weak cytotoxicity. Consequently, based on this discovery, the present invention provides a novel substance having a proliferation-inhibition activity on Mycobacterium tuberculosis.
従来技術、競合技術の概要(英語) BACKGROUND ART
2 Tuberculosis infection is specified to include 3 and 1 is one large infection, HIV/AIDS infections include the following single 2 a large number of deaths in the world the second disease. 1,040 Tuberculosis million patient reported that, by year 170 million people died tuberculosis (2016 years, WHO). HIV infection in the user, the tuberculosis 1 5 occupy the third leading cause of death. With respect to the treatment of tuberculosis, as first, rifampicin, isoniazid, ethambutol, streptomycin, ethambutol is, as the second choice, levofloxacin, kanamycin, antileprosy, , para-aminosalicylic acid, cycloserine been used, used in combination of two or more agents 3.
In recent years, a multi-drug resistance resistant to a therapeutic agent of tuberculosis is, the trend for the spread. Rifampicin resistant to the drug of choice for 60 years may be applied to a case of the upstream one million, 49 million of them are multi-drug resistance is considered. Multidrug resistant tuberculosis further and the existing anti-tuberculosis drug resistant tuberculosis shown no effect on the appearance of an ultra-multi-more than half of the world seen in the countries, these measures are in the urgent international society has been a problem.
However, these therapeutic agents by reducing the number of patients newly industrialized countries in association with, the development of new anti-tuberculosis drugs is reduced, the new anti-tuberculosis agent is 40 years on the market and also not 1. Multidrug-resistant tuberculosis and as one of measures against tuberculosis of the ultra-multi, effective against these, in the conventional structure and mechanism of action of therapeutic agents of the different is demanded the development of new therapeutic agents.
Such as an anti-tuberculosis drug, nitroimidazole-based compound, such as CPZEN-45/caprazamycin, Clp protease and the disturbance material has been studied (Non-Patent Document 1). Clp protease disturbance material which is one type of marine is cyclo marin (cyclomarin) from Streptomyces sp. obtained from actinomycetes in heptapeptides. Is cyclo marin, tuberculosis ClpC1 Clp of the action of the sub-units, and run the function to induce cell death. Streptomyces atratusSCSIO ZH16 iramaishin from deep water is isolated from the cyclo marin and analogous compounds, Clp protease disturbance material in the same manner as thought. C of a plurality of homologs iramaishin iramaishin represented by the following structure is a compound, the compound activity against drug resistant tuberculosis (Mycobacteria tuberculosis H37Rv) have been reported to be as low as 9.6μm (Non-Patent Document 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • THE KITASATO INSTITUTE
  • HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • OMURA Satoshi
  • SHIOMI Kazuro
  • MORI Mihoko
  • MATSUMOTO, Atsuko
  • SUZUKI, Yasuhiko
  • NAKAJIMA, Chie
  • YAMAGUCHI Tomoyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close